

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8620 - KKR / WBA / PHARMERICA

SECTION 1.2

Description of the concentration

1. The Commission has received notification of a proposed concentration pursuant to article 4 of Council Regulation (EC) No 139/2004 (the “EUMR”). On 30 August 2017, KKR & Co. L.P. (“KKR”) and Walgreens Boots Alliance, Inc. (“WBA”) notified their intention to acquire indirect joint control of PharMerica Corporation (“PharMerica”) within the meaning of Article 3(1)(b) of the EUMR.
2. The areas of activities of the undertakings concerned by the notified concentration are as follows:
 - i) KKR – Global investment firm which offers a broad range of alternative asset management services to public and private market investors and provides capital markets solutions for the firm, its portfolio companies and clients.
 - ii) WBA – Global pharmacy-led, health and wellbeing enterprise, operating retail pharmacies across the United States and Europe, as well as a global pharmaceutical wholesale and distribution network, with distribution centres delivering to pharmacies, doctors, health centres and hospitals in more than 20 countries
 - iii) PharMerica – Provides long term care pharmacy, infusion therapy, and specialty pharmacy services in the United States.